Diabetic Kidney Disease Treatment Study

Diabetic Kidney Disease affects approximately one in four people living with diabetes and can have serious impacts on health. Being the single leading cause of kidney failure, it is important to continually develop better treatments so kidney health can be more effectively managed.

That is why Doherty Clinical Trials are conducting the Diabetic Kidney Disease Treatment Study to test a potential new treatment that is designed to target a key inflammation pathway. This new treatment has the potential to slow down disease progression or even reverse disease. This study aims to better understand the safety and tolerability of this potential new treatment in healthy people and people living with diabetes who have impaired kidney function.

This study involves a screening visit, an 8-night stay at the Doherty Clinical Trials unit (East Melbourne) and an additional 4 clinic visits over approximately 3 months.

DKD is a long-term complication of diabetes that damages the kidneys over time. DKD happens when high blood sugar levels cause inflammation and scarring in the kidneys. This scarring is known as fibrosis and can reduce how well the kidneys work and may eventually lead to kidney failure. People with DKD may experience swelling, high blood pressure, protein in the urine, and reduced kidney function. Over time, kidney damage can become permanent.

The results of this study will help researchers decide whether the study drug should continue to be developed as a possible treatment for people with DKD.